Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time
- PMID: 14751359
- DOI: 10.1016/j.urology.2003.08.011
Treatment options for localized prostate cancer: quality-adjusted life years and the effects of lead-time
Abstract
Objectives: The purposes of this study were to estimate the difference in quality-adjusted life-years between conservative management and prostatectomy or radiotherapy (RT) by clinical Gleason score (2 to 4, 5 to 6, 7, and 8 to 10) for patients aged 55 years and older with clinically localized prostate cancer and to adjust for and explore the effects of lead-time. For localized prostate cancer, it is not known whether treatment (prostatectomy or RT) results in longer quality-adjusted survival than conservative management. Observed survival benefits after treatment may be biased by the lead-time resulting from early diagnosis with prostate-specific antigen screening.
Methods: A Markov simulation was developed, and transition probabilities were derived from a review of published studies. Utility weights were measured in male volunteers older than 60 years. Estimates of disease progression during conservative management were adjusted for lead-time. Sensitivity analyses were performed on all parameters (including estimates for lead-time).
Results: For Gleason score 2 to 4 cancer, conservative management yielded the greatest number of quality-adjusted life-years. For Gleason score 5 to 6 cancer, any of the options appeared beneficial, depending on the estimates for disease progression. For Gleason score 7 to 10 cancer, prostatectomy and RT resulted in more quality-adjusted life-years than conservative management; with a lead-time adjustment of greater than 10 years, the outcomes with conservative management and prostatectomy were similar. The choice between prostatectomy and RT was sensitive to estimates of disease progression after treatment.
Conclusions: Conservative management is a reasonable option for Gleason score 2 to 4 cancer and for some patients with Gleason score 5 to 6 cancer. Prostatectomy or RT is recommended for Gleason score 7 to 10 cancer. The survival benefits after treatment were not explained by the lead-time alone.
Similar articles
-
Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes.Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1220-5. doi: 10.1016/s0360-3016(01)01558-9. Int J Radiat Oncol Biol Phys. 2001. PMID: 11483332
-
A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival.Br J Cancer. 2006 May 22;94(10):1361-8. doi: 10.1038/sj.bjc.6603105. Br J Cancer. 2006. PMID: 16641912 Free PMC article.
-
Radical retropubic prostatectomy in men younger than 45 years diagnosed during early prostate cancer detection program.Urology. 2004 Feb;63(2):337-41. doi: 10.1016/j.urology.2003.09.032. Urology. 2004. PMID: 14972485
-
No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer.Urology. 2004 Mar;63(3):528-31. doi: 10.1016/j.urology.2003.09.064. Urology. 2004. PMID: 15028451 Review.
-
[Quality of life after radiotherapy for prostate cancer].Cancer Radiother. 2010 Oct;14(6-7):519-25. doi: 10.1016/j.canrad.2010.06.015. Epub 2010 Aug 21. Cancer Radiother. 2010. PMID: 20728393 Review. French.
Cited by
-
Association between utility and treatment among patients with prostate cancer.Qual Life Res. 2010 Jun;19(5):711-20. doi: 10.1007/s11136-010-9622-8. Epub 2010 Mar 5. Qual Life Res. 2010. PMID: 20204704
-
A decision aid for intensity-modulated radiation-therapy plan selection in prostate cancer based on a prognostic Bayesian network and a Markov model.Artif Intell Med. 2009 Jun;46(2):119-30. doi: 10.1016/j.artmed.2008.12.002. Epub 2009 Jan 20. Artif Intell Med. 2009. PMID: 19157811 Free PMC article.
-
Cost-effectiveness of MR Imaging-guided Strategies for Detection of Prostate Cancer in Biopsy-Naive Men.Radiology. 2017 Oct;285(1):157-166. doi: 10.1148/radiol.2017162181. Epub 2017 May 17. Radiology. 2017. PMID: 28514203 Free PMC article.
-
Quantitative ultrasound spectroscopic imaging for characterization of disease extent in prostate cancer patients.Transl Oncol. 2015 Feb;8(1):25-34. doi: 10.1016/j.tranon.2014.11.005. Transl Oncol. 2015. PMID: 25749174 Free PMC article.
-
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.JAMA. 2010 Dec 1;304(21):2373-80. doi: 10.1001/jama.2010.1720. JAMA. 2010. PMID: 21119084 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical